Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vibha Sharma

Vibha Sharma is a senior reporter covering pharmaceutical and medtech regulatory developments across the globe. She joined Scrip Regulatory Affairs in September 2010 and has since then been at the center of deciding and writing news on important regulatory issues affecting the pharma and medtech sectors and explaining their implications for the industry.

Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.

Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.

Advertisement
Set Alert for Articles By Vibha Sharma

Latest From Vibha Sharma

Research-Based Pharma Urges Redress From Negative Impact Of EU SPC Waiver

The research-based pharmaceutical industry has issued a severe warning that the European Parliament's overwhelming support for IP-related changes that will allow manufacturing of generics and biosimilars during the term of supplementary protection certificates will hit innovation. Some of industry's concerns may be justified, a patent attorney explains.
Europe Intellectual Property

WHO Consults On Remaining Shelf-Life Policy For Medical Products

The World Health Organization has framed a policy to help suppliers, donors, procurers and distributors manage medical products throughout the supply chain and ensure availability within their remaining shelf-life.

International Regulation

WHO Consults On Remaining Shelf-Life Policy For Medical Products

The World Health Organization has framed a policy to help suppliers, donors, procurers and distributors manage medical products throughout the supply chain and ensure availability within their remaining shelf-life.
International Regulation

EU Clarifies Interplay Between CTR And GDPR

A Q&A document from the European Commission elaborates on alternative legal bases, other than informed consent, for processing clinical trial data under the General Data Protection Regulation.
Europe Clinical Trials

Pharma Told To Maintain Drug Stockpiles Despite Six-Month Brexit Delay

An agreement to delay Brexit has brought no reprieve for the pharmaceutical sector, which must remain at a heightened state of preparedness as a no-deal scenario is still a possibility. Industry says it will seek clarity on the practical implications of this.
Europe United Kingdom

UK Legislators Get Involved In NICE’s Methods Review

A UK parliamentary panel examining a wide range of issues affecting the availability of new treatments on the National Health Service is collecting evidence on possible topics that might be covered under the upcoming review of the appraisal methods used by health technology assessment body NICE. NICE itself is not publicly consulting on the scope of the review.
United Kingdom Health Technology Assessment
See All
Advertisement
UsernamePublicRestriction

Register